Summit Therapeutics reports Q4 2023 GAAP net loss $36.6M; cash runway extended to Q1 2025 via $100M CEO note amendment

Summit Therapeutics Inc.

2023-FY EPS reported -$0.99

GAAP net loss Q4 2023 $36.6M ($0.05/sh) vs $19.3M ($0.07/sh) a year ago; full-year loss $614.9M primarily from $500M ivonescimab licensing fee.
Cash and equivalents, restricted cash, and short-term investments $186.2M at Dec 31, 2023, down from $648.6M at Dec 31, 2022.
Extended cash runway guidance to Q1 2025 from Q3 2024 after amending $100M CEO note to April 1, 2025 maturity with interest rate >12%.
Actively enrolling two Phase III trials (HARMONi and HARMONi-3) for ivonescimab in NSCLC; HARMONi enrollment completion expected H2 2024.
Updated Phase II data: 24-month OS rate 64.8% in 1L squamous NSCLC; median OS 22.5 months in 2L+ EGFR-mutant NSCLC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Summit Therapeutics Inc. updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 20, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.